Measuring progression in frontotemporal dementia: implications for therapeutic interventions
Measuring progression in frontotemporal dementia: implications for therapeutic interventions
Background: there is a need for instruments which can measure progression of disease in frontotemporal dementia (FTD), particularly with respect to the assessment of potential therapeutic agents.
Methods: the Cambridge Early Onset Dementia Clinic database was reviewed for all prospectively enrolled cases of FTD with documented scores on the Mini-Mental State Examination (MMSE) or Addenbrooke’s Cognitive Examination (ACE) on at least two occasions. We identified 50 cases fulfilling these criteria: pathologic confirmation was present in 11 of 16 patients who had died, 12 of the remainder had imaging abnormalities on their initial scans, and 22 had structural scans no different from controls. We compared these groups to a cohort with early AD (n = 25) and healthy controls (n = 10).
Results: There was clear cognitive decline (measured by the MMSE and ACE) in patients who had died, and those with documented atrophy on initial MRI scan. In contrast, patients with FTD with normal scans showed no change in cognitive scores over a much longer interval, and serial ACE measurements paralleled those of controls. Power calculations showed that the inclusion of these patients with FTD would significantly increase the number of cases needed in any therapeutic trial.
Conclusion: Addenbrooke’s Cognitive Examination is a simple monitoring tool which can detect progression of disease in frontotemporal dementia over a 1- to 2-year interval without the need for serial imaging. We estimated that a clinical trial that enrolled subjects with abnormal MR scans would require 135 subjects per group to detect a small effect, and 35 for a medium effect.
2046-2052
Kipps, C.M.
e43be016-2dc2-45e6-9a02-ab2a0e0208d5
Nestor, P.J.
058a7998-7d59-447f-b8d3-24f7a48ae5a7
Dawson, C.E.
c92dfca8-943f-470b-a337-2aae4f4142f4
Mitchell, J.
1ba1021f-d0e0-4465-b09a-d5eb976b7173
Hodges, J.R.
c17af0a9-82e7-4f5a-8a97-d50ec06bbb0a
27 May 2008
Kipps, C.M.
e43be016-2dc2-45e6-9a02-ab2a0e0208d5
Nestor, P.J.
058a7998-7d59-447f-b8d3-24f7a48ae5a7
Dawson, C.E.
c92dfca8-943f-470b-a337-2aae4f4142f4
Mitchell, J.
1ba1021f-d0e0-4465-b09a-d5eb976b7173
Hodges, J.R.
c17af0a9-82e7-4f5a-8a97-d50ec06bbb0a
Kipps, C.M., Nestor, P.J., Dawson, C.E., Mitchell, J. and Hodges, J.R.
(2008)
Measuring progression in frontotemporal dementia: implications for therapeutic interventions.
Neurology, 70 (22), .
(doi:10.1212/01.wnl.0000313366.76973.8a).
Abstract
Background: there is a need for instruments which can measure progression of disease in frontotemporal dementia (FTD), particularly with respect to the assessment of potential therapeutic agents.
Methods: the Cambridge Early Onset Dementia Clinic database was reviewed for all prospectively enrolled cases of FTD with documented scores on the Mini-Mental State Examination (MMSE) or Addenbrooke’s Cognitive Examination (ACE) on at least two occasions. We identified 50 cases fulfilling these criteria: pathologic confirmation was present in 11 of 16 patients who had died, 12 of the remainder had imaging abnormalities on their initial scans, and 22 had structural scans no different from controls. We compared these groups to a cohort with early AD (n = 25) and healthy controls (n = 10).
Results: There was clear cognitive decline (measured by the MMSE and ACE) in patients who had died, and those with documented atrophy on initial MRI scan. In contrast, patients with FTD with normal scans showed no change in cognitive scores over a much longer interval, and serial ACE measurements paralleled those of controls. Power calculations showed that the inclusion of these patients with FTD would significantly increase the number of cases needed in any therapeutic trial.
Conclusion: Addenbrooke’s Cognitive Examination is a simple monitoring tool which can detect progression of disease in frontotemporal dementia over a 1- to 2-year interval without the need for serial imaging. We estimated that a clinical trial that enrolled subjects with abnormal MR scans would require 135 subjects per group to detect a small effect, and 35 for a medium effect.
This record has no associated files available for download.
More information
e-pub ahead of print date: 27 May 2008
Published date: 27 May 2008
Identifiers
Local EPrints ID: 489365
URI: http://eprints.soton.ac.uk/id/eprint/489365
ISSN: 0028-3878
PURE UUID: 8a69b28d-60ec-45fa-8f30-87d13d3d6ff8
Catalogue record
Date deposited: 23 Apr 2024 16:31
Last modified: 24 Apr 2024 01:56
Export record
Altmetrics
Contributors
Author:
C.M. Kipps
Author:
P.J. Nestor
Author:
C.E. Dawson
Author:
J. Mitchell
Author:
J.R. Hodges
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics